The company expressed its excitement for the development of SHR-4849, highlighting its potential therapeutic benefits in ...

The U.K.'s Medicines and Healthcare products Regulatory Agency has approved Amgen's (NASDAQ:AMGN) tarlatamab, also known as ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Imdyllytra (tarlatamab) for the ...

The Medicines and Healthcare products Regulatory Agency of the United Kingdom announced it has approved the medicine tarlatamab, Imdyllytra, to ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab ...

Obrixtamig is under clinical development by Boehringer Ingelheim International and currently in Phase I for Small-Cell Lung Cancer.

Ideaya Biosciences, Inc. has recently announced an exclusive license agreement for SHR-4849, a novel DLL3-targeting ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Nasopharyngeal Cancer.

Highlights,IDEAYA secures exclusive global license for SHR-4849, a promising ADC targeting Small Cell Lung Cancer ...

INR:8459. players only sign Overview of new drugs approved worldwide in December 2019 SCLC is about to usher in more new therapies after immunotherapy breaks th ...

Researchers conducted a retrospective study to examine the prognostic roles of Neutrophil-to-Lymphocyte Ratio (NLR) and ...

Secondary prevention for lung cancer involves screening methods that aim to detect the disease in its early stages, before ...